OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
Mark P. Lythgoe, Jonathan Krell, Mark Bower, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 4, pp. e150-e160
Open Access | Times Cited: 12
Mark P. Lythgoe, Jonathan Krell, Mark Bower, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 4, pp. e150-e160
Open Access | Times Cited: 12
Showing 12 citing articles:
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100840-100840
Open Access | Times Cited: 15
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100840-100840
Open Access | Times Cited: 15
The future of cancer care in the UK—time for a radical and sustainable National Cancer Plan
Ajay Aggarwal, Ananya Choudhury, Nicola Fearnhead, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. e6-e17
Open Access | Times Cited: 16
Ajay Aggarwal, Ananya Choudhury, Nicola Fearnhead, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. e6-e17
Open Access | Times Cited: 16
Cancer medicines: a private vice for public benefit?
Richard Sullivan
ecancermedicalscience (2024) Vol. 18
Open Access | Times Cited: 3
Richard Sullivan
ecancermedicalscience (2024) Vol. 18
Open Access | Times Cited: 3
Outsourcing UK regulatory decisions—a double-edged sword?
Mark P. Lythgoe, Richard Sullivan
The Lancet (2023) Vol. 402, Iss. 10395, pp. 24-25
Open Access | Times Cited: 4
Mark P. Lythgoe, Richard Sullivan
The Lancet (2023) Vol. 402, Iss. 10395, pp. 24-25
Open Access | Times Cited: 4
Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis
Mark P. Lythgoe, Alica‐Joana Emhardt, Huseyin Naci, et al.
The Lancet Regional Health - Europe (2024) Vol. 46, pp. 101062-101062
Open Access | Times Cited: 1
Mark P. Lythgoe, Alica‐Joana Emhardt, Huseyin Naci, et al.
The Lancet Regional Health - Europe (2024) Vol. 46, pp. 101062-101062
Open Access | Times Cited: 1
Another setback for cancer research in the UK
Mark P. Lythgoe, Richard Sullivan
BMJ (2023), pp. e077036-e077036
Closed Access | Times Cited: 3
Mark P. Lythgoe, Richard Sullivan
BMJ (2023), pp. e077036-e077036
Closed Access | Times Cited: 3
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies
Mark P. Lythgoe, Richard Sullivan, Sarah P. Blagden
The Lancet Oncology (2023) Vol. 24, Iss. 9, pp. 963-966
Closed Access | Times Cited: 2
Mark P. Lythgoe, Richard Sullivan, Sarah P. Blagden
The Lancet Oncology (2023) Vol. 24, Iss. 9, pp. 963-966
Closed Access | Times Cited: 2
Review time of oncology drugs and its underlying factors: an exploration in China
Xingyue Zhu, Bao Liu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 1
Xingyue Zhu, Bao Liu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 1
Access Divergence to New Cancer Medicines in the United Kingdom
Mark P. Lythgoe, Sarah P. Blagden, Susannah Stanway, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114131-114131
Closed Access
Mark P. Lythgoe, Sarah P. Blagden, Susannah Stanway, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114131-114131
Closed Access
Hospital factors influencing the mobility of patients for systemic therapies in breast and bowel cancer in the metastatic setting: a national population-based evaluation
Lu Han, David Josephs, Jacqueline Boyle, et al.
Clinical Oncology (2024) Vol. 36, Iss. 10, pp. e398-e407
Open Access
Lu Han, David Josephs, Jacqueline Boyle, et al.
Clinical Oncology (2024) Vol. 36, Iss. 10, pp. e398-e407
Open Access
As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022
Alexander D. VanHelene, Matthew J. Hadfield, Dario Trapani, et al.
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000410-e000410
Open Access
Alexander D. VanHelene, Matthew J. Hadfield, Dario Trapani, et al.
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000410-e000410
Open Access
Managing Clinical Trials Amid Healthcare Policy Reforms: Challenges and Opportunities
Babar Hayat, Nazia Mumtaz, Sadia Choudry, et al.
Pakistan Journal of Health Sciences (2024), pp. 304-312
Closed Access
Babar Hayat, Nazia Mumtaz, Sadia Choudry, et al.
Pakistan Journal of Health Sciences (2024), pp. 304-312
Closed Access
